结合Aptamer和Mitomycin C与降解剂反应链接剂导致协同增强的抗癌作用
Qiuxia Yang1, Zhengyu Deng1, Dan Wang1
1Molecular Sciences and Biomedicine Laboratory (MBL), State Key Laboratory for Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering and College of Biology, Collaborative Innovation Center for Chemistry and Molecular Medicine , Hunan University , Changsha 410082 , China.
通过向癌细胞来增强癌症治疗的Aptamer-mitomycin C结合物. 一种二硫酸结合器策略显著提高了药物的有效性,并减少了消化道癌症的副作用.
科学领域:
- 生物结合化学
- 癌症治疗方法
- 药物输送系统
背景情况:
- 甲素C (MMC) 用于消化道癌症,但由于非特异性DNA化,具有严重的副作用.
- 有针对性的药物供应对于改善MMC的治疗指数和尽量减少毒性至关重要.
- 药剂提供了一个有前途的化学疗法提供平台.
研究的目的:
- 设计和开发用于向癌症治疗的新型阿普坦-米托米辛C合物.
- 研究不同交叉连接化学物质对结合剂疗效的影响.
- 评估链接剂依赖的细胞毒性和增强药物递送的机制基础.
主要方法:
- 通过各种交叉连接策略,包括二硫化键,合成阿普坦-MMC合物.
- 在体外评估结合向能力,细胞吸收和对癌细胞系的细胞毒性.
- 机理学研究阐明了体识别,结合和内化作用.
主要成果:
- 与自由的MMC相比,APTAMER-MMC结合物显示有针对性的递送和增强的细胞毒性.
- 使用减少剂敏感的二硫化键结合剂的结合物显著提高了疗效.
- 在不同类型的细胞毒性中观察到细胞毒性增强,证实了该设计的多功能性.
- 目标识别,特异性结合和受体介导的内细胞分裂对于观察到的效果至关重要.
结论:
- 阿普塔默与药物结合物,特别是带有二硫化物结合剂的药物,是增强MMC在消化道癌症治疗中的有效策略.
- 这种方法有效地改善了药物向性,并克服了非特异性药物作用的局限性.
- 这些发现突显了基于aptamer的药物输送系统在开发更安全,更有效的癌症疗法方面的潜力.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
